142 related articles for article (PubMed ID: 4350685)
1. [Therapy of primary hyperlipoproteinemia types IIa, IIb and IV using beta pyridylcarbinol Study on three phases under ambulatory conditions].
Klemens UH; von Löwis P
Dtsch Med Wochenschr; 1973 Jun; 98(24):1197-202. PubMed ID: 4350685
[No Abstract] [Full Text] [Related]
2. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
[TBL] [Abstract][Full Text] [Related]
3. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
Rouffy J; Dreux C; Goussault Y; Dakkak R; Renson FJ
Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788
[TBL] [Abstract][Full Text] [Related]
4. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(12):1682-4. PubMed ID: 6686774
[TBL] [Abstract][Full Text] [Related]
5. Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia.
Olsson AG; Rössner S; Walldius G; Carlson LA
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):28-31. PubMed ID: 190607
[TBL] [Abstract][Full Text] [Related]
6. [Lipid composition of circulating lipoproteins in various types of hyperlipoproteinemia (author's transl)].
Jaillard J; Sezille G; Dewailly P; Fruchart JC
Diabete Metab; 1977 Sep; 3(3):159-64. PubMed ID: 199484
[TBL] [Abstract][Full Text] [Related]
7. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G
Therapie; 1978; 33(5):615-22. PubMed ID: 217121
[No Abstract] [Full Text] [Related]
8. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
Haacke H; Parwaresch MR; Mäder C
Med Klin; 1977 Jul; 72(27):1183-7. PubMed ID: 196168
[TBL] [Abstract][Full Text] [Related]
9. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
[TBL] [Abstract][Full Text] [Related]
10. [Clinical testing of a combination of clofibrate and beta-pyridylcarbinol in an unusual dosis relation].
Mann S; Maisenbacher HJ
Z Allgemeinmed; 1975 Aug; 51(24):1066-71. PubMed ID: 1101545
[No Abstract] [Full Text] [Related]
11. Does hypolipidemic therapy prevent coronary heart disease?
Rifkind BM; Levy RI
Cardiovasc Clin; 1974; 6(2):1-8. PubMed ID: 4374303
[No Abstract] [Full Text] [Related]
12. Effect of a new niacin derivative (nicotinic hexaester of D-glucitol) on type IIA, IIB and IV hyperlipoproteinemia in man.
Avogaro P; Bittolo-Bon G; Pais M; Taroni GC
Pharmacol Res Commun; 1977 Jun; 9(6):599-606. PubMed ID: 197548
[No Abstract] [Full Text] [Related]
13. [The relationship of cholesterol (CHO) and triglycerides (TG) in VLDL, LDL, and VLDL subfractions by agarose gel electrophoresis, using CHO and TG dual staining (AG-CHO, TG staining)].
Miyake N; Iizuka K
Rinsho Byori; 2002 Jun; 50(6):605-12. PubMed ID: 12166081
[TBL] [Abstract][Full Text] [Related]
14. Bile acid kinetics and steroid balance during nicotinic acid therapy in patients with hyperlipoproteinemia types II and IV.
Einarsson K; Hellström K; Leijd B
J Lab Clin Med; 1977 Oct; 90(4):613-22. PubMed ID: 198500
[No Abstract] [Full Text] [Related]
15. Clinical evaluation of cinnarizine in hyperlipaemic patients.
Saba P; Galeone F; Salvadorini F; Guarguaglini M; Houben JL
G Clin Med; 1974 Aug; 55(8):586-99. PubMed ID: 4377134
[No Abstract] [Full Text] [Related]
16. Studies in asymptomatic primary hyperlipidaemia. IV. ECG at rest and during exercise and its relation to various lipoprotein classes.
Olsson AG; Ekelund LG; Carlson LA
Acta Med Scand; 1975; 198(1-2):55-73. PubMed ID: 170796
[TBL] [Abstract][Full Text] [Related]
17. [Beta-sitosterin in unsuccessfully pretreated patients with hypercholesteremia. Simultaneously, a contribution to dose dependence].
Mühlfellner G; Mühlfellner O; Kaffarnik H
Med Klin; 1976 Apr; 71(18):775-8. PubMed ID: 178987
[TBL] [Abstract][Full Text] [Related]
18. The effect of beta-pyridylcarbinol on lipoprotein lipids in primary type IIa hyperlipoproteinemia.
Schwandt P; Weisweiler P; Neureuther G
Atherosclerosis; 1979 Sep; 34(1):35-9. PubMed ID: 227427
[TBL] [Abstract][Full Text] [Related]
19. Antilipidemic drugs. Part 6: LF 178 in man. A preliminary note on a multicenter investigation bearing on 393 subjects with pure or mixed forms of hyperlipidemia.
Wülfert B; Majoie B; de Ceaurriz A
Arzneimittelforschung; 1976; 26(5):906-9. PubMed ID: 183789
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R
MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
